



CALIFORNIA TECHNOLOGY ASSESSMENT FORUM<sup>SM</sup>

## Mepolizumab for the Treatment of Severe Asthma with Eosinophilia: Effectiveness, Value, and Value-Based Price Benchmarks

### Questions for Deliberation: February 12, 2016 Public Meeting

1. For patients with severe asthma and with an eosinophilic phenotype, is the evidence adequate to demonstrate that the net health benefit of adding *mepolizumab to standard of care* is greater than that of *standard of care alone*?  
Yes            No
  
2. Given the available evidence for patients with severe asthma and with an eosinophilic phenotype, what is the care value\* of adding *mepolizumab to standard of care* vs. *standard of care alone*?  
a. Low        b. Intermediate        c. High
  
3. Given the available evidence for patients with severe asthma and with an eosinophilic phenotype, what is the provisional health system value\*\* of adding *mepolizumab to standard of care* vs. *standard of care alone*?  
a. Low        b. Intermediate        c. High

\* **Care value** is determined by looking at four elements: comparative clinical effectiveness, incremental costs per outcomes achieved, other benefits or disadvantages, and contextual considerations. Care value represents the long-term perspective, at the individual patient level, on patient benefits and the incremental costs to achieve those benefits.

\*\* **Provisional health system value** represents a judgment integrating consideration of the long-term care value of a new intervention with an analysis of its potential short-term budget impact if utilization is unmanaged.